# GCC Allergy Immunotherapy Market > GCC Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) and By Patient Type (Pediatric, Adult, Geriatric) - Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.43% - **2018:** $ 266 Million - **2024:** $ 84.9 Million - **2035:** $ 228.81 Million - **Key Players:** Allergopharma (DE), AstraZeneca (GB), Boehringer Ingelheim (DE), GlaxoSmithKline (GB), Merck Group (DE), Novartis (CH), Sanofi (FR), Stallergenes Greer (GB) **Report ID:** MRFR/HC/54528-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-allergy-immunotherapy-market-56294 --- ## Market Summary **GCC Allergy Immunotherapy Market Overview****:** **As per MRFR analysis, the GCC Allergy Immunotherapy Market Size was estimated at 266 (USD Million) in 2023. The GCC Allergy Immunotherapy Market Industry is expected to grow from 285.5(USD Million) in 2024 to 687.5 (USD Million) by 2035. The GCC Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 8.317% during the forecast period (2025 - 2035).** **Key GCC Allergy Immunotherapy Market Trends Highlighted** The GCC Allergy Immunotherapy Market is experiencing substantial growth, which is primarily due to the increasing prevalence of allergic conditions in the region. The demand for effective treatment options has increased as a result of the increase in allergies, which has been influenced by urbanization, environmental factors, and a growing population. The advancement of medical technology has facilitated the creation of novel immunotherapy products and treatment protocols, thereby improving patient outcomes. Additionally, the market is being further stimulated by the growing public and governmental awareness of the significance of allergy management. In the GCC region, there has been a discernible trend toward personalized medicine in the recent past. Healthcare providers are emphasizing personalized treatments that are based on the unique profiles of each patient, which is consistent with the global trend toward more personalized healthcare solutions. The integration of digital health technologies, such as telemedicine and mobile health applications, is also revolutionizing the way patients access immunotherapy, rendering it more patient-friendly and accessible. Opportunities for exploration include the establishment of partnerships between pharmaceutical companies and research organizations in the GCC to expedite the development of novel immunotherapy products. These partnerships have the potential to result in improved clinical research and trials, with a particular emphasis on the distinctive allergens that are present in the GCC climate, including pollen and dust mites.Additionally, the expanding healthcare infrastructure in countries such as the United Arab Emirates and Saudi Arabia provides opportunities to increase the availability and distribution of immunotherapy treatments. Additionally, there is potential to enhance education and awareness campaigns that target both healthcare professionals and the general public to raise awareness of the advantages of immunotherapy as a sustainable solution for allergy sufferers in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **GCC Allergy Immunotherapy Market Drivers** Increasing Prevalence of Allergies The GCC Allergy Immunotherapy Market Industry is witnessing a significant surge in demand due to the increasing prevalence of allergic diseases across the Gulf Cooperation Council countries. Studies indicate that approximately 30% of the population in cities like Riyadh and Doha suffers from allergic rhinitis, which is a primary driver for immunotherapy treatments. Organizations such as the Qatar University of Science and Technology have shown through their research that environmental factors like dust and pollen lead to heightened allergy rates, further necessitating immunotherapy options.This growing awareness and need for effective treatment underscore the potential for significant market expansion in the region. Government Initiatives and Health Policies The GCC Allergy Immunotherapy Market Industry is benefiting from active government initiatives aimed at improving healthcare services focused on allergy treatment. For instance, the Saudi Ministry of Health has rolled out several public health campaigns promoting allergy awareness and diagnosis. This strategy includes allocating resources for Research and Development in allergy immunotherapy techniques. Such government support is crucial as it not only helps in raising public awareness but also lays the groundwork for new treatment facilities, thereby driving growth in the market. Technological Advancements in Immunotherapy Technological advancements in the GCC Allergy Immunotherapy Market Industry are significantly driving growth prospects. Innovations such as sublingual immunotherapy, which simplifies the delivery of allergens, are gaining momentum across the GCC region. Companies like Almana Group and Riyadh Pharma are investing heavily in Research and Development to refine these methods. Given that the World Health Organization has identified that technological enhancements can improve patient compliance and success rates in treatments, the GCC region is poised for a substantial increase in value within its allergy immunotherapy market. Growing Awareness and Acceptance of Immunotherapy There is rising awareness regarding allergy immunotherapy as an effective long-term treatment option among healthcare professionals and patients in the GCC region. Through various awareness programs led by local health organizations and hospitals, there has been an increase in the number of consultations regarding allergy treatment. For example, the Emirates Allergy Society has reported a 25% increase in inquiries about immunotherapy options over the past three years.This trend indicates a shift in public perception towards preventive and curative treatment, ultimately driving the growth of the GCC Allergy Immunotherapy Market Industry. **GCC Allergy Immunotherapy Market Segment Insights****:** **Allergy Immunotherapy Market Type Insights****** **** The GCC Allergy Immunotherapy Market is demonstrating significant growth and innovation across its Type segment, which includes Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. The overall evaluation from experts shows that the market exhibits an increasing demand for these therapies due to the rising prevalence of allergic diseases in the region. The lifestyle changes and environmental factors in GCC countries, such as higher urbanization rates and industrialization, are contributing to a surge in allergy cases, thereby propelling the need for effective immunotherapy. Among these therapies, Subcutaneous Immunotherapy is often favored due to its long-standing history and effectiveness in treating allergies. This involves administering allergens through injections over a period, helping the immune system to build tolerance. Sublingual Immunotherapy has also gained traction as it offers a convenient alternative, allowing patients to place allergen tablets under their tongue, which can be done at home, thus improving patient adherence. Furthermore, Oral Immunotherapy is emerging as a promising approach, especially for food allergies, as it allows gradual exposure to the allergens through ingestion. Each of these types addresses specific patient needs and preferences, contributing to their respective growth.In GCC, particularly, awareness campaigns and educational initiatives by health authorities are crucial in driving acceptance and understanding of these treatment options. Given the region's emphasis on healthcare advancements, policymakers support regulatory frameworks facilitating the availability of these therapies. Additionally, the increasing health expenditure and advancements in medical technologies amplify the GCC Allergy Immunotherapy Market's appeal, offering a competitive edge for innovators in the field. Despite these advancements, challenges such as the necessity for continuous patient education and varied accessibility to treatment remain. However, there are substantial opportunities for growth, particularly in developing personalized therapies that suit the diverse population in the GCC. The dynamic landscape of allergy management in this region ensures that each segment within the Type category is poised to contribute to an evolving healthcare narrative focused on enhancing patient outcomes and overall quality of life. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Allergy Immunotherapy Market Product Insights****** **** The GCC Allergy Immunotherapy Market is expanding steadily, with various products playing a vital role in addressing allergic conditions across the region. Allergen extracts form a significant part of this market, as they are essential in desensitization therapies, providing targeted treatment to individuals suffering from specific allergies. Conventional immunotherapy remains a cornerstone in allergy treatments, offering time-tested methods for long-term management of allergic rhinitis and other conditions, which continue to be highly sought after by patients.The increasing adoption of biologics represents a noteworthy trend, with these advanced therapies showing efficacy in treating severe allergic reactions and asthma related to allergies. This evolution reflects a shift towards personalized medicine within the GCC region, enhancing treatment outcomes and patient satisfaction. The GCC government is placing a strong emphasis on healthcare innovation and the development of novel allergy treatments, contributing to the market's growth. The ongoing investment in healthcare infrastructure and awareness campaigns further supports the demand for diverse product options within the GCC Allergy Immunotherapy Market, indicating a robust landscape for growth and innovation. **Allergy Immunotherapy Market Indication Insights****** **** The GCC Allergy Immunotherapy Market, particularly in the context of Indication, comprises various conditions that are increasingly prevalent within the region. Allergic Rhinitis holds significant importance due to its high incidence caused by environmental factors, such as dust and pollen, prevalent in GCC countries. Allergic Asthma also remains a key focus, driven by rising pollution levels and lifestyle changes, requiring effective immunotherapy options to manage symptoms. Atopic Dermatitis is gaining attention as well, particularly among younger populations, reflecting the necessity for tailored treatment strategies.Additionally, Food Allergies present growing concerns as dietary habits evolve and awareness increases, underlying the need for comprehensive immunotherapy solutions. The segmentation emphasizes a targeted approach, wherein each indication warrants specific therapies, thus driving innovation within the GCC Allergy Immunotherapy Market. Market growth is supported by increasing healthcare expenditure, advances in research and development, and heightened awareness about allergy management among healthcare professionals and the public. Combined, these factors underline the dynamic nature of the GCC Allergy Immunotherapy Market, fostering opportunities for stakeholders to develop effective treatments addressing these critical health issues. **Allergy Immunotherapy Market Patient Type Insights****** **** The GCC Allergy Immunotherapy Market, particularly when considering the Patient Type segment, reveals critical insights into the diverse demographic needs across the region. This market is characterized by three main categories: Pediatric, Adult, and Geriatric patient groups, each with unique considerations and treatment requirements. Pediatric patients often face an increasing prevalence of allergic conditions, necessitating early intervention and tailored immunotherapy solutions to manage their sensitivities effectively. Adult patients represent a significant portion of the market, driven by lifestyle factors and environmental changes that exacerbate allergies, leading to a growing demand for effective treatment options.Meanwhile, the Geriatric population is gaining attention due to their increased vulnerability to allergies and the challenges posed by comorbidities, highlighting the need for targeted immunotherapy programs that cater to their health complexities. Overall, the GCC Allergy Immunotherapy Market segmentation reflects the importance of a comprehensive approach to allergy management, which caters to the varying needs of these patient types in the region, ensuring that treatments are both accessible and effective for all age groups. **GCC Allergy Immunotherapy Market Key Players and Competitive Insights****:** The GCC Allergy Immunotherapy Market is characterized by a dynamic competitive landscape driven by rising allergic disorders and increasing prevalence of allergic rhinitis and asthma within the region. This market is marked by a growing demand for innovative treatments and therapies aimed at desensitizing patients to allergens, with various pharmaceutical firms vying for market leadership. The competitive landscape is underscored by significant investments in research and development, enhanced distribution strategies, and strategic collaborations to boost product offerings. As companies explore new therapies and applications of immunotherapy, the competitive insights reveal a focus on understanding local healthcare needs, regulatory frameworks, and the overall healthcare environment that shapes the Gulf Cooperation Council countries. Pfizer has established a notable presence in the GCC Allergy Immunotherapy Market, bolstered by its reputation for high-quality pharmaceutical products and cutting-edge research. The company has focused on developing allergy treatments that cater to the specific market needs in the Gulf region, leveraging its extensive global expertise while tailoring offerings to address local healthcare challenges. Pfizer's strengths lie in its robust research and development capabilities, a comprehensive portfolio of allergy immunotherapy products, and a well-established distribution network throughout the GCC. This enables Pfizer to efficiently reach healthcare providers and patients alike, ensuring accessible treatments for the millions suffering from allergies in the region.AbbVie also plays a significant role in the GCC Allergy Immunotherapy Market, capitalizing on its expertise in immunology and evolving treatment modalities. The company is known for its diverse range of immunotherapies and seeks to address unmet needs within the Gulf region’s allergy treatment landscape. Key products in AbbVie's portfolio focus on both allergy relief and overall immunological health, supported by substantial investments in clinical research. The company has made strides with strategic mergers and acquisitions that augment its capabilities in allergy immunotherapy, enabling it to enhance and expand its product offerings. With its solid market presence and commitment to innovation, AbbVie continues to build on its strengths, ensuring that it remains a competitive player in the GCC Allergy Immunotherapy Market as it addresses the rising demands for effective allergy management solutions. **Key Companies in the GCC Allergy Immunotherapy Market Include:** Pfizer AbbVie Stallergenes Greer Merck Group Aimmune Therapeutics GlaxoSmithKline ALKAbello Boehringer Ingelheim Novartis Sanofi Allergopharma GmbH HollisterStier Allergy Mylan N.V. Meda Pharmaceuticals Aldena **GCC Allergy Immunotherapy Market Industry Developments** _The GCC Allergy Immunotherapy Market has recently witnessed significant advancements, particularly following the rising incidence of allergic conditions in the region. Companies like Pfizer and AbbVie are focusing on Research and Development to enhance treatment options. In September 2023, Merck Group announced progress in clinical trials for its immunotherapy products targeting allergens prevalent in GCC countries, which has sparked interest among healthcare professionals and patients alike. Meanwhile, Stallergenes Greer and Aimmune Therapeutics have been collaborating with local clinics to improve accessibility to immunotherapy treatments in urban areas. Notably, in June 2023, GlaxoSmithKline secured a partnership with the Saudi Arabian Ministry of Health to implement awareness campaigns about allergy management, further emphasizing the regional commitment to address allergy challenges. There have been no recent acquisitions reported among the key players like Boehringer Ingelheim and Sanofi, which could suggest a focus on strengthening their market positions independently. The market is expected to grow in valuation due to these initiatives, impacting the treatment landscape in the GCC, where the prevalence of allergies continues to rise, especially among children. Major incidents impacting the market over the last couple of years include the regulatory approvals for new allergen immunotherapy products in late 2022._ **GCC Allergy Immunotherapy Market Segmentation Insights** **Allergy Immunotherapy Market Type****Outlook** **Subcutaneous Immunotherapy** **Sublingual Immunotherapy** **Oral Immunotherapy** **Allergy Immunotherapy Market Product****Outlook** **Allergen Extracts** **Conventional Immunotherapy** **Biologics** **Allergy Immunotherapy Market Indication****Outlook** **Allergic Rhinitis** **Allergic Asthma** **Atopic Dermatitis** **Food Allergies** **Allergy Immunotherapy Market Patient Type****Outlook** **Pediatric** **Adult** **Geriatric** **** ## Market Drivers ### Rising Healthcare Expenditure The GCC [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market is positively influenced by the increasing healthcare expenditure across the region. Governments and private sectors are allocating more resources to healthcare, which includes funding for allergy treatments. According to recent reports, healthcare spending in the GCC is projected to reach USD 104 billion by 2025, with a significant portion directed towards allergy management. This increase in funding is likely to enhance the availability of immunotherapy options, making them more accessible to patients. As healthcare systems evolve to accommodate advanced treatment modalities, the market for allergy immunotherapy is expected to grow, driven by improved patient access and treatment options. ### Increasing Awareness of Allergies The GCC Allergy Immunotherapy Market is experiencing a notable surge in awareness regarding allergies and their management. Public health campaigns and educational initiatives by governments and health organizations are contributing to this trend. For instance, the prevalence of allergic rhinitis in the GCC region is estimated to affect around 30% of the population, prompting a greater demand for effective treatment options. This heightened awareness is likely to drive the adoption of immunotherapy as a viable solution, as patients seek long-term relief from allergy symptoms. Furthermore, the growing understanding of the benefits of immunotherapy over traditional treatments is expected to enhance patient engagement and compliance, thereby expanding the market for allergy immunotherapy in the GCC. ### Government Initiatives and Funding The GCC Allergy Immunotherapy Market is bolstered by various government initiatives aimed at improving healthcare outcomes. Governments in the region are increasingly investing in allergy research and treatment programs, recognizing the burden of allergic diseases on public health. For example, the Saudi Ministry of Health has launched initiatives to enhance allergy diagnosis and treatment, which includes funding for immunotherapy research. Such governmental support not only facilitates the development of innovative therapies but also encourages healthcare providers to adopt immunotherapy practices. This financial backing is likely to stimulate market growth, as it enables the introduction of advanced treatment modalities and increases accessibility for patients across the GCC. ### Technological Advancements in Treatment The GCC Allergy Immunotherapy Market is witnessing rapid technological advancements that are transforming treatment methodologies. Innovations such as sublingual immunotherapy and the development of personalized allergy vaccines are gaining traction. These advancements are supported by research institutions and pharmaceutical companies focusing on enhancing the efficacy and safety of immunotherapy. For instance, the introduction of digital health solutions for monitoring patient responses to treatment is expected to improve adherence and outcomes. As these technologies become more integrated into clinical practice, they are likely to attract more patients seeking effective allergy management, thereby expanding the market for allergy immunotherapy in the GCC. ### Growing Demand for Alternative Therapies The GCC Allergy Immunotherapy Market is experiencing a shift in patient preferences towards alternative therapies for allergy management. As individuals become more informed about the limitations of conventional treatments, there is a growing inclination towards immunotherapy as a long-term solution. This trend is particularly evident among patients seeking to avoid the side effects associated with antihistamines and corticosteroids. The increasing demand for holistic and natural treatment options is likely to propel the adoption of immunotherapy in the GCC. Furthermore, as healthcare providers recognize the efficacy of immunotherapy, they are more inclined to recommend it, thereby fostering market growth in the region. ## Future Outlook The GCC Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising healthcare expenditure. **New opportunities:** - Expansion of personalized immunotherapy solutions for diverse patient demographics. Development of mobile health applications for real-time allergy management. Investment in advanced manufacturing technologies for cost-effective allergen production. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in allergy treatment solutions. ## Segment Insights ### By Application: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing) In the GCC Allergy Immunotherapy Market, Allergic Rhinitis represents the largest segment, commanding a significant share due to its high prevalence in urban populations exposed to allergens such as pollen, dust mites, and pet dander. This has resulted in increased demand for effective treatment options, making it a primary focus for healthcare providers and pharmaceutical companies. Allergic Asthma, on the other hand, is emerging as the fastest-growing segment, driven by rising air pollution levels and lifestyle changes, leading to a greater incidence of asthma among the population. Allergic Rhinitis (Dominant) vs. Allergic Asthma (Emerging) Allergic Rhinitis remains the dominant application in the GCC Allergy Immunotherapy Market, benefiting from established treatment protocols and a well-informed patient base seeking relief from symptoms. Its strong market presence is supported by a wide range of available therapies, including subcutaneous and sublingual immunotherapy options. Conversely, Allergic Asthma, as the emerging segment, is gaining traction due to the increasing recognition of asthma management's importance and the ongoing development of innovative treatment methodologies. The need for personalized medicine and more effective therapies tailored to specific patient profiles is driving research and investment in this area, positioning Allergic Asthma as a key focus for future growth. ### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing) In the GCC Allergy Immunotherapy Market, Subcutaneous Immunotherapy holds the largest share, primarily due to its established efficacy and widespread acceptance among healthcare professionals and patients. This method has become the traditional approach for treating allergies, driving its dominance in the market. Sublingual Immunotherapy, while smaller in share, is quickly gaining traction as a viable alternative, appealing particularly to patients seeking convenience and reduced administration time. The growth trends for these segment values are influenced by various factors. The shift towards more patient-friendly administration methods has underscored the appeal of Sublingual Immunotherapy, catering to the growing demand for non-invasive treatment options. Additionally, increased awareness and education surrounding allergy management are driving market expansion, as patients and practitioners actively seek effective immunotherapy solutions to enhance quality of life. Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging) Subcutaneous Immunotherapy is recognized as the dominant method of allergy treatment within the GCC region, thanks to its long track record of success and extensive clinical support. This modality involves injecting allergen extracts to gradually desensitize the immune system, allowing for durable and lasting responses. Conversely, Sublingual Immunotherapy is emerging as a preferred alternative, as it allows patients to take their medication under the tongue, fostering greater adherence due to its ease of use and eliminating the need for injections. Both therapies are essential in providing tailored solutions, but their delivery methods reflect broader trends toward patient-centered healthcare, positioning Sublingual Immunotherapy as a compelling option for those looking for more comfortable treatment paths. ### By Patient Demographics: Pediatric Patients (Largest) vs. Geriatric Patients (Fastest-Growing) In the GCC Allergy Immunotherapy Market, the segmentation by patient demographics reveals that pediatric patients constitute the largest share, reflecting a significant proportion of the overall patient population seeking allergy treatments. Adult patients also represent a considerable market segment, although they lag behind pediatrics in overall demand. Geriatric patients, while currently a smaller demographic, show an increasing inclination towards immunotherapy, influenced by rising allergy incidences and a growing awareness of treatment benefits in later stages of life. Pediatric Patients (Dominant) vs. Geriatric Patients (Emerging) Pediatric patients are the dominant group in the GCC Allergy Immunotherapy Market, primarily driven by the early onset of allergies in children and increasing parental awareness regarding effective treatment options. This segment benefits from a robust healthcare framework focusing on childhood diseases. Conversely, geriatric patients are emerging as a significant market, propelled by an aging population that is increasingly affected by environmental and genetic allergy triggers. The growing acceptance of immunotherapy among older adults, along with advancements in treatment tailored for this age group, signifies a promising future for this segment as awareness and accessibility continue to improve. ### By Treatment Duration: Maintenance Treatment (Largest) vs. Induction Treatment (Fastest-Growing) In the GCC Allergy Immunotherapy Market, the Treatment Duration segment reveals a diverse distribution among its various categories. The maintenance treatment continues to hold the largest market share due to its established efficacy and preference among practitioners for long-term patient management. Conversely, induction treatment is rapidly gaining traction as more healthcare professionals are adopting this method, leading to its recognition as the fastest-growing option within the segment. As consumer awareness regarding allergic conditions rises, the demand for effective immunotherapy solutions like induction treatment is expected to surge. Factors such as increasing prevalence of allergies, improved healthcare accessibility, and advancements in treatment protocols are driving growth in this segment. The emphasis on personalized treatment plans is also fostering innovation and attracting more patients seeking timely interventions to alleviate allergy symptoms. Maintenance Treatment (Dominant) vs. Induction Treatment (Emerging) In the GCC Allergy Immunotherapy Market, maintenance treatment stands out as the dominant approach, providing patients with sustained relief from allergic symptoms. This treatment typically involves administering regular doses over an extended period, ensuring enhanced immune system responsiveness. The established presence and clinical efficacy of this method contribute to its market leadership. On the other hand, induction treatment is emerging rapidly, characterized by its potential for quicker symptom alleviation and shorter initial exposure times. This approach is increasingly appealing to patients looking for immediate results and is supported by growing clinical research backing its effectiveness. Both treatment methods cater to diverse patient needs, positioning them as critical components of the GCC allergy immunotherapy landscape. ## Competitive Benchmarking The GCC Allergy Immunotherapy Market is currently characterized by a dynamic competitive landscape, driven by increasing allergy prevalence and a growing awareness of immunotherapy as a viable treatment option. Key players such as Allergopharma (DE), AstraZeneca (GB), and Merck Group (DE) are strategically positioned to leverage innovation and regional expansion to enhance their market presence. Allergopharma (DE) focuses on developing advanced allergen immunotherapy products, while AstraZeneca (GB) emphasizes partnerships to broaden its therapeutic offerings. Merck Group (DE) is investing in [digital transformation](https://www.marketresearchfuture.com/reports/digital-transformation-market-8685) to optimize patient engagement and treatment adherence, collectively shaping a competitive environment that prioritizes innovation and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in treatment methodologies and patient access initiatives, thereby enhancing the overall market structure. In January 2026, AstraZeneca (GB) announced a strategic partnership with a regional healthcare provider to enhance access to its allergy immunotherapy products across the GCC. This collaboration is expected to facilitate better patient outreach and education, ultimately increasing treatment uptake. The strategic importance of this partnership lies in its potential to expand AstraZeneca's footprint in a rapidly growing market, aligning with the company's goal of improving patient outcomes through innovative therapies. In December 2025, Merck Group (DE) launched a new digital platform aimed at improving patient engagement in allergy immunotherapy. This platform is designed to provide personalized treatment plans and real-time monitoring, which could significantly enhance patient adherence to therapy. The launch underscores Merck's commitment to integrating technology into its offerings, positioning the company as a leader in patient-centric care within the allergy immunotherapy sector. In November 2025, Allergopharma (DE) received regulatory approval for a new sublingual immunotherapy product, marking a significant milestone in its product portfolio. This approval not only diversifies Allergopharma's offerings but also reflects the company's focus on innovation in treatment modalities. The introduction of this product is likely to strengthen Allergopharma's competitive position by addressing unmet patient needs in the GCC region. As of February 2026, current trends in the GCC Allergy Immunotherapy Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the growing demand for effective allergy treatments. ## Recent News & Developments _The GCC Allergy Immunotherapy Market has recently witnessed significant advancements, particularly following the rising incidence of allergic conditions in the region. Companies like Pfizer and AbbVie are focusing on Research and Development to enhance treatment options. In September 2023, Merck Group announced progress in clinical trials for its immunotherapy products targeting allergens prevalent in GCC countries, which has sparked interest among healthcare professionals and patients alike. Meanwhile, Stallergenes Greer and Aimmune Therapeutics have been collaborating with local clinics to improve accessibility to immunotherapy treatments in urban areas. Notably, in June 2023, GlaxoSmithKline secured a partnership with the Saudi Arabian Ministry of Health to implement awareness campaigns about allergy management, further emphasizing the regional commitment to address allergy challenges. There have been no recent acquisitions reported among the key players like Boehringer Ingelheim and Sanofi, which could suggest a focus on strengthening their market positions independently. The market is expected to grow in valuation due to these initiatives, impacting the treatment landscape in the GCC, where the prevalence of allergies continues to rise, especially among children. Major incidents impacting the market over the last couple of years include the regulatory approvals for new allergen immunotherapy products in late 2022._ ## Report Scope Report Scope: | Report Attribute/Metric Source: | Details | | --- | --- | | MARKET SIZE 2018 | 266.0(USD Million) | | MARKET SIZE 2024 | 285.5(USD Million) | | MARKET SIZE 2035 | 687.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.317% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | MARKET FORECAST PERIOD | 2025 - 2035 | | HISTORICAL DATA | 2019 - 2024 | | MARKET FORECAST UNITS | USD Million | | KEY COMPANIES PROFILED | Pfizer, AbbVie, Stallergenes Greer, Merck Group, Aimmune Therapeutics, GlaxoSmithKline, ALKAbello, Boehringer Ingelheim, Novartis, Sanofi, Allergopharma GmbH, HollisterStier Allergy, Mylan N.V., Meda Pharmaceuticals, Aldena | | SEGMENTS COVERED | Type, Product, Indication, Patient Type | | KEY MARKET OPPORTUNITIES | Rising allergy prevalence rates, Increased demand for personalized therapies, Expansion of telemedicine services, Growing awareness of immunotherapy benefits, Government support and funding initiatives | | KEY MARKET DYNAMICS | rising allergy prevalence, increasing healthcare expenditure, technological advancements, growing awareness and education, favorable government regulations | | COUNTRIES COVERED | GCC | ## Frequently Asked Questions **Q: What is the current valuation of the GCC Allergy Immunotherapy Market?** A: The market valuation was 84.9 USD Million in 2024. **Q: What is the projected market size for the GCC Allergy Immunotherapy Market by 2035?** A: The market is projected to reach 228.81 USD Million by 2035. **Q: What is the expected CAGR for the GCC Allergy Immunotherapy Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 9.43%. **Q: Which applications dominate the GCC Allergy Immunotherapy Market?** A: Allergic Rhinitis and Allergic Asthma are leading applications, with valuations of 30.0 and 25.0 USD Million respectively. **Q: What types of immunotherapy are prevalent in the GCC market?** A: Sublingual Immunotherapy and Subcutaneous Immunotherapy are prominent, valued at 25.0 and 20.0 USD Million respectively. **Q: How does patient demographics affect the GCC Allergy Immunotherapy Market?** A: Adult Patients represent a significant segment, with a valuation of 45.0 USD Million. **Q: What treatment durations are considered in the GCC Allergy Immunotherapy Market?** A: Long-term Treatment and Maintenance Treatment are key segments, valued at 25.0 and 20.0 USD Million respectively. **Q: Who are the key players in the GCC Allergy Immunotherapy Market?** A: Key players include Allergopharma, AstraZeneca, and Merck Group among others. **Q: What is the market outlook for allergic rhinitis treatment in the GCC?** A: The allergic rhinitis segment is expected to grow, with a valuation range of 30.0 to 80.0 USD Million. **Q: What trends are anticipated in the GCC Allergy Immunotherapy Market by 2035?** A: The market is likely to expand significantly, driven by increasing awareness and advancements in immunotherapy. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-allergy-immunotherapy-market-56294*